References

Update on multiple endocrine neoplasia type 1 and 2

10.1016/j.lpm.2018.03.005 · 2018 · External reference

Breast-cancer predisposition in multiple endocrine neoplasia type 1

10.1056/nejmc1406028 · 2014 · External reference

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

10.1126/science.aax5863 · 2020 · External reference

A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia

10.1016/j.ccell.2019.11.001 · 2019 · External reference

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis

10.1016/j.cell.2005.09.025 · 2005 · External reference

Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development

10.1038/onc.2016.315 · 2017 · External reference

The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis

10.1146/annurev-biochem-051710-134100 · 2012 · External reference

COMPASS: a complex of proteins associated with a trithorax-related SET domain protein

10.1073/pnas.231473398 · 2001 · External reference

The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers

10.1128/mcb.01181-13 · 2013 · External reference

Molecular regulation of histone H3 trimethylation by COMPASS and the regulation of gene expression

10.1016/j.molcel.2005.07.024 · 2005 · External reference

Epigenetic balance of gene expression by polycomb and compass families

10.1126/science.aad9780 · 2016 · External reference

Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS

10.1128/mcb.00976-08 · 2008 · External reference

Identification and characterization of the human Set1B histone H3-Lys 4 methyltransferase complex

10.1074/jbc.m609809200 · 2007 · External reference

SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53

10.1016/j.cell.2013.06.027 · 2013 · External reference

Not all H3K4 methylations are created equal: Mll2/COMPASS dependency in primordial germ cell specification

10.1016/j.molcel.2017.01.013 · 2017 · External reference

Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II

10.1128/mcb.00924-09 · 2009 · External reference

An Mll-dependent Hox program drives hematopoietic progenitor expansion

10.1016/j.cub.2004.11.012 · 2004 · External reference

Enhancer-associated H3K4 monomethylation by trithorax-related, the drosophila homolog of mammalian MLL3/MLL4

10.1101/gad.201327.112 · 2012 · External reference

H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation

10.7554/elife.01503 · 2013 · External reference

Challenges and opportunities in targeting the menin-MLL interaction

10.4155/fmc.13.214 · 2014 · External reference

Menin links estrogen receptor activation to histone H3K4 trimethylation

10.1158/0008-5472.can-05-4461 · 2006 · External reference

Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus

10.1016/s1097-2765(04)00081-4 · 2004 · External reference

Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression

10.1128/mcb.24.13.5639-5649.2004 · 2004 · External reference

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression

10.1073/pnas.0510347103 · 2006 · External reference

Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality

10.1038/sj.onc.1204174 · 2001 · External reference

Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors

10.1073/pnas.0408836102 · 2005 · External reference

The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor γ-dependent adipocyte differentiation

10.1128/mcb.01001-08 · 2009 · External reference

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

10.1038/ng765 · 2002 · External reference

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation

10.1182/blood-2002-10-3221 · 2003 · External reference

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT

10.1038/leu.2010.155 · 2010 · External reference

Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9

10.1101/gad.1111603 · 2003 · External reference

Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential

10.1101/gad.1602107 · 2007 · External reference

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 di- and tri-methylation on target genes and transformation potential

10.1016/j.celrep.2015.04.004 · 2015 · External reference

Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications

10.1158/0008-5472.can-05-1041 · 2005 · External reference

AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia

10.1016/j.molcel.2010.01.026 · 2010 · External reference

Pharmacologic inhibition of the menin-MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma

10.1158/1535-7163.mct-17-0580 · 2018 · External reference

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia

10.1172/jci129126 · 2020 · External reference

A Box of chemistry to inhibit the MEN1 tumor suppressor gene promoting leukemia

10.1002/cmdc.202000972 · 2021 · External reference

Unresolved reference

2024 · External reference

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

10.1038/s41586-023-05812-3 · 2023 · External reference

2024 Update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia

10.3390/hematolrep16020024 · 2024 · External reference

Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription

10.1016/s0092-8674(00)80967-8 · 1999 · External reference

Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes

10.1128/mcb.01742-12 · 2013 · External reference

AP-1 in cell proliferation and survival

10.1038/sj.onc.1204383 · 2001 · External reference

AP-1 as a regulator of cell life and death

10.1038/ncb0502-e131 · 2002 · External reference

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

10.1007/bf00666036 · 1995 · External reference

JunB regulates angiogenesis and neurovascular parallel alignment in mouse embryonic skin

10.1242/jcs.196303 · 2017 · External reference

AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis

10.1074/jbc.m110.106187 · 2010 · External reference

Transcription factors control invasion: AP-1 the first among equals

10.1038/sj.onc.1209759 · 2007 · External reference

Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers

10.1073/pnas.1821068116 · 2019 · External reference

AP-1 transcription factors as regulators of immune responses in cancer

10.3390/cancers11071037 · 2019 · External reference

JUND promotes tumorigenesis via specifically binding on enhancers of multiple oncogenes in cervical cancer

2023 · External reference

JunD is required for proliferation of prostate cancer cells and plays a role in transforming growth factor-β (TGF-β)-induced inhibition of cell proliferation

10.1074/jbc.m116.714899 · 2016 · External reference

JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer

10.1172/jci.insight.124985 · 2021 · External reference

JunD mediates survival signaling by the JNK signal transduction pathway

10.1016/s1097-2765(03)00203-x · 2003 · External reference

Two proteins translated by alternative usage of initiation codons in mRNA encoding a JunD transcriptional regulator

10.1006/bbrc.1998.9331 · 1998 · External reference

Regulation of two JunD isoforms by Jun N-terminal kinases

10.1074/jbc.m204552200 · 2002 · External reference

The same pocket in menin binds both MLL and JUND but has opposite effects on transcription

10.1038/nature10806 · 2012 · External reference

Multiple tumor suppressor pathways negatively regulate telomerase

10.1016/s0092-8674(03)00430-6 · 2003 · External reference

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival

10.1186/s12964-023-01335-6 · 2023 · External reference

Chromatin-modifying enzymes as modulators of reprogramming

10.1038/nature10953 · 2012 · External reference

SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets

10.1016/j.gpb.2022.01.004 · 2022 · External reference

Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition under hypoxia

10.3390/ijms23137051 · 2022 · External reference

Chaperonin CCT checkpoint function in basal transcription factor TFIID assembly

10.1038/s41594-018-0156-z · 2018 · External reference

Molecular determinants for recognition of serotonylated chromatin

10.1093/nar/gkaf612 · 2025 · External reference

Integrating quantitative proteomics with accurate genome profiling of transcription factors by greenCUT&RUN

10.1093/nar/gkab038 · 2021 · External reference

Improved CUT&RUN chromatin profiling tools

10.7554/elife.46314 · 2019 · External reference

greenCUT&RUN: efficient genomic profiling of GFP-tagged transcription factors and chromatin regulators

10.1002/cpz1.266 · 2021 · External reference

greenPipes: an integrated data analysis pipeline for greenCUT&RUN and CUT&RUN genome-localization datasets

10.1093/bioinformatics/btae307 · 2024 · External reference

Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration

10.1128/mcb.00982-14 · 2015 · External reference

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity

10.1186/s13072-022-00461-8 · 2022 · External reference

Menin: a scaffold protein that controls gene expression and cell signaling

10.1016/j.tibs.2013.05.005 · 2013 · External reference

MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia

10.1038/onc.2016.488 · 2017 · External reference

MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia

10.1016/j.celrep.2016.12.054 · 2017 · External reference

Selective inhibitors for JNK signalling: a potential targeted therapy in cancer

10.1080/14756366.2020.1720013 · 2020 · External reference

Discovery of potent and selective covalent inhibitors of JNK

10.1016/j.chembiol.2011.11.010 · 2012 · External reference

MEN1 mutations mediate clinical resistance to menin inhibition

10.1038/s41586-023-05755-9 · 2023 · External reference

Ultraviolet-induced junD activation and apoptosis in myeloblastic leukemia ML-1 cells

10.1074/jbc.m203519200 · 2002 · External reference

NF-κB regulation in the immune system

10.1038/nri910 · 2002 · External reference